Physician profile
Mark Matthews
NPI 1245348390
$3,385.65
in general payments reported to CMS, 2019-2025
41 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $511 · 2021: $728 · 2022: $304 · 2023: $185 · 2024: $881 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $368.68 | 2019-2022 | |
| Amgen INC. | $290.72 | 2019-2025 | Tepezza, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $275.11 | 2019-2025 | |
| Novo Nordisk INC | $242.61 | 2021-2025 | Wegovy |
| Ucb, INC. | $207.23 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals Lp | $202.45 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.27 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $138.33 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.12 | 2023-2025 | Ofev, Jardiance |
| Pfizer INC. | $134.88 | 2019-2022 | |
| Medtronic, INC. | $125.81 | 2021-2024 | Cobalt Dr Mri Surescan |
| Astellas Pharma US INC | $120.86 | 2019 | |
| Alexion Pharmaceuticals, INC. | $81.44 | 2023-2024 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $78.04 | 2021-2022 | |
| Boston Scientific Corporation | $77.33 | 2019-2022 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.14 | 2021 | |
| Averitas Pharma INC. | $62.24 | 2024 | Qutenza |
| Lilly USA, LLC | $58.83 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $45.67 | 2024 | Rexulti |
| Radius Health, INC. | $42.04 | 2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $42.03 | 2024-2025 | |
| Corcept Therapeutics | $39.52 | 2024 | Korlym |
| Lantheus Medical Imaging, INC. | $37.49 | 2020-2021 | |
| Daiichi Sankyo INC. | $36.76 | 2024-2025 | Injectafer |
| Aurinia Pharma U.S., INC. | $34.86 | 2024 | Lupkynis |
| Chiesi USA, INC. | $29.48 | 2021 | |
| Kyowa Kirin, INC. | $26.04 | 2024 | Crysvita |
| Ge Healthcare | $25.77 | 2020 | |
| Vital Connect, INC | $23.37 | 2024 | Vitalpatch Rtm |
| Horizon Therapeutics Plc | $20.44 | 2023 | Krystexxa |
| Abbvie INC. | $20.04 | 2025 | |
| Cvrx, INC. | $19.36 | 2023 | Barostim Neo System |
| My01 INC. | $17.87 | 2025 | My01 Continuous Compartmental Pressure Monitor |
| Fresenius Kabi USA, LLC | $16.78 | 2025 | |
| Esperion Therapeutics, INC. | $15.05 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $14.99 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $14.02 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $13.37 | 2024 | Arexvy, Shingrix |
| Integra Lifesciences Corporation | $11.88 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.70 | 2021 | |
| Janssen Scientific Affairs, LLC | $10.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.